Decitabine

製品コードS1200 別名:Deoxycytidine

Decitabine化学構造

分子量(MW):228.21

Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS).

サイズ 価格(税別)  
JPY 25730.00
JPY 14940.00
JPY 28220.00
JPY 53120.00
JPY 94620.00

カスタマーフィードバック(3)

  • (A) and (B) SW1116 and LOVO cells were plated, treated for 48 h with decitabine (DAC) and gefitinib (GEF) either alone or in combination, and the expression levels of AKT, mTOR, S6K, and phosphorylation were determined by Western blot analysis as described under Methods. Expression of β-actin served as a loading control. The data are representative of three independent experiments.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

    (A) and (B) SW1116 and LOVO cells were cultured in control conditions (DMSO) or in the presence of the indicated concentrations of decitabine (DAC) and gefitinib (GEF), alone or in combination, for 48 h. And then cells were stained with Annexin V-FITC and propidium iodide (PI) and analyzed by flow cytometry. This experiment was done in triplicate and representative diagrams of Annexin V-FITC assays are shown.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

  • Leuk Res 2014 38(3), 402-10. Decitabine purchased from Selleck.

製品安全説明書

DNA Methyltransferase阻害剤の選択性比較

生物活性

製品説明 Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS).
ターゲット
DNA methylation [1]
(HL-60, KG1a cells)
体外試験

Decitabine inhibits cell growth in a dose and time-dependent manner with IC50 of approximately 438 nM and 43.8 nM for 72 hours and 96 hours exposure in HL-60 and KG1a leukemic cells, respectively. [1] A recent study shows that Decitabine exhibits high anti-proliferative and pro-apoptotic activity against anaplastic large cell lymphoma (ALCL), and inhibits [3H]–thymidine uptake in KARPAS-299 cells with EC50 of 0.49 μM. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Eca109 MWHGeY5kfGmxbjDBd5NigQ>? MkmwNE42yqEQvF2= MlPUNlQhcA>? MYT3ZZRmeg>? NHLxZ|dud2S3bHH0[ZMhfGinIHflcoUh\XiycnXzd4lwdiCxZjDNRWdGNUFibXXtZoVzew>? M{nyfVI2OTJ|MEiy
Eca109 NFnqWopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIKwR5oxNjVxMj61M|Uh|ryP NYO2eG8zOjRxNEivO|IhcA>? Mn7ne4F1\XJ? M4XVc4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIgh\G:|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK= NXOzPYZ5OjVzMkOwPFI>
Eca109 M{n2WGZ2dmO2aX;uJGF{e2G7 NHXTWmIxNjYEoN88US=> NELoTJo3NzF{L{K0JIg> M{W5RpdifGW{ M1vhfYlvcGmkaYTzJINmdGxibXnndoF1cW:wwrC= NFvROo8zPTF{M{C4Ni=>
Eca109 MYHGeY5kfGmxbjDBd5NigQ>? MUSwMlXDqM7:TR?= Ml;KNlQhcA>? MXH3ZZRmeg>? NUfTT|VWcW6qaXLpeJMh[2WubDDpcpZie2mxbh?= M1nnR|I2OTJ|MEiy
Eca109 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLWNE42yqEQvF2= M{Syb|I1KGh? NYjvT3pvf2G2ZYK= M{fQVYlv\HWlZYOgS|IwVSCjcoLld5QhcW5idHjlJINmdGxiY4njcIU> MWKyOVEzOzB6Mh?=
Eca109 Ml7USpVv[3Srb36gRZN{[Xl? NYLROHVPOC53L{Gg{txO NISybmYzPCCq NEHuPWt4[XSnch?= NWeyR|U1\GWlcnXhd4V{KGW6cILld5Nqd25ib3[gUmYu|rqEMjDhcoQhVU2SMh?= MknQNlUyOjNyOEK=
SW1116  NWP3V3hFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUmwMlUwOS9{L{Wg{txO MV60PEBp MXrEUXNQ Mkew[Y5p[W6lZYOgeIhmKEenZnn0bY5q[iCrbnT1Z4VlKGOnbHygbY5pcWKrdHnvci=> NIDlV|YzPDh5NEK4Oi=>
LOVO Ml3FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlX2NE42NzFxMj:1JO69VQ>? M3zJWlQ5KGh? M4LC[2ROW09? MXTlcohidmOnczD0bIUhT2WoaYTpcoljKGmwZIXj[YQh[2WubDDpcohq[mm2aX;u M1fIUFI1QDd2Mki2
SW1116  MmjaSpVv[3Srb36gRZN{[Xl? MVOxNEDPxE1? M{WycFQ5KGh? MmT1SG1UVw>? NIDtcYJqdmO{ZXHz[ZMhfGinIHXm[oVkfGm4ZTDheEBqdmirYnn0bY5oKEGNVDDhcoQhdVSRUjDzbYdv[WyrbnegdIF1cHejeYOgZ49u[mmwZXSge4l1cCCpZX\peIlvcWJ? NUixUldCOjR6N{SyPFY>
LOVO M1n2UmZ2dmO2aX;uJGF{e2G7 MWOxNEDPxE1? MXe0PEBp MmXzSG1UVw>? MVfpcoNz\WG|ZYOgeIhmKGWoZnXjeIl3\SCjdDDpcohq[mm2aX7nJGFMXCCjbnSgcXRQWiC|aXfuZYxqdmdicHH0bJdigXNiY3;tZolv\WRid3n0bEBo\W[rdHnubYI> Mn;hNlQ5PzR{OE[=
SW1116  NV;vPWN3SXCxcITvd4l{KEG|c3H5 MmPJNVAh|ryP NHP0WWE1QCCq NFuwW4pFVVOR MlTJ[Y5p[W6lZYOgS4VncXSrbnniMYlv\HWlZXSgZZBweHSxc3nz NHPme4kzPDh5NEK4Oi=>
LOVO NXLkS2VCSXCxcITvd4l{KEG|c3H5 NITHWmkyOCEQvF2= MXy0PEBp NEfkW2RFVVOR NGSzc49mdmijbnPld{BI\W[rdHnubYIucW6mdXPl[EBieG:ydH;zbZM> NVrvUJFPOjR6N{SyPFY>
RPMI-8226 MkfuRZBweHSxc3nzJGF{e2G7 NUjobI5vOS9{IN88US=> NUThSZVwPDhxN{KvPVYhcA>? NUj1SnlnTE2VTx?= NW\yVm9zcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MnjKNlQ5OzNzMEi=
OPM-2  M1TISmFxd3C2b4Ppd{BCe3OjeR?= NELuSmIyNzJizszN Mo[wO|IwQTZxMUKwJIg> Ml\lSG1UVw>? M3nrVIlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NHHi[ZkzPDh|M{GwPC=>
JJN3  NUjKTXVSSXCxcITvd4l{KEG|c3H5 Mk\5NE42NzFizszN Mn7xNlQwPDhiaB?= MXXEUXNQ MkXsbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? Mo\UNlQ5OzNzMEi=
NCI-H929  NYHYd4pWSXCxcITvd4l{KEG|c3H5 MWOxM|Ih|ryP NV3ObYl[PzJxOU[vNVIxKGh? MlPHSG1UVw>? NU[xOIFFcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NILjPJgzPDh|M{GwPC=>
RPMI-8226 M3\PcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXteIJxOS9{IN88US=> NUHifIw4OjRxNEivO|IhcA>? NHLYU49FVVOR NUPaWmhn[W[oZXP0d{Bk\WyuIHP5Z4xmKHC{b3fy[ZN{cW:wIH7l[4F1cX[nbIm= NV;oNIV2OjR6M{OxNFg>
OPM-2  NVHZcWZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVu3[|RWOS9{IN88US=> MXyyOE81QC95MjDo MkjoSG1UVw>? MkjyZYZn\WO2czDj[YxtKGO7Y3zlJJBzd2e{ZYPzbY9vKG6nZ3H0bZZmdHl? M{DDSlI1QDN|MUC4
JJN3  NILFRVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUWwMlUwOSEQvF2= NW\nTJZ7OjRxNEivO|IhcA>? NXHPR45lTE2VTx?= MmPaZYZn\WO2czDj[YxtKGO7Y3zlJJBzd2e{ZYPzbY9vKG6nZ3H0bZZmdHl? MXKyOFg{OzFyOB?=
NCI-H929  MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1j5eVEwOiEQvF2= NXHBUmFnOjRxNEivO|IhcA>? NYjJeWg2TE2VTx?= NFroUWxi\m[nY4TzJINmdGxiY4njcIUheHKxZ4Lld5Nqd25ibnXnZZRqfmWueR?= M1H1cFI1QDN|MUC4
HeLa NXLte2MzU2mwYYPlJGF{e2G7 MWPLbV0yODBy4pETOVAxOCEQvF2g[o9zKGiHTmSx NHTJPY0zPDd6MEC5PC=>
HeLa MkjpT4lv[XOnIFHzd4F6 M2PtXmtqRTVwNjFCtUAxNjVizszNJIZweiCqRV7UNi=> MmrXNlQ4QDByOUi=
HeLa MoPhT4lv[XOnIFHzd4F6 MkHZT4k:OjFwNjFCtUA{NjBizszNJIZweiCqQ17UNS=> NUTXWIgxOjR5OECwPVg>
HeLa MkPYT4lv[XOnIFHzd4F6 M{mzT2tqRTF2LkSgxtEhPC54IN88UUBnd3JiaFPOWFM> MoTCNlQ4QDByOUi=
NB4 MVfGeY5kfGmxbjDBd5NigQ>? NVjtOGxpOi53L{WvO{42NzFyIN88US=> M1j4PVI1KGh? NVvufnhWTE2VTx?= NYrCPIR[cW6lcnXhd4ViKHSqZTDlfJBz\XO|aX;uJI9nKHC{ZXP1dpNweiCvaWKtNVI2[Q>? NEjQe5kzPDR6NEi3NC=>
CD4+ CD25− T  M{Dkc2Z2dmO2aX;uJGF{e2G7 MkewNU82KM7:TR?= MlHudoVlfWOnUzDncI9j[WxiRF7BJI1mfGi7bHH0bY9v MlHMNlQ1PzZ|NkC=
BV-173 NWPqb5NXSXCxcITvd4l{KEG|c3H5 MkWwNE4zPS9yLkWvNE44PS9zIN88US=> M2LrfFQ5Nzd{L{m2JIg> NIr4b|PDqFCEUx?= NHjjd25qdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI> Ml6wNlQ1OjN4MUO=
ML-1 MlrqRZBweHSxc3nzJGF{e2G7 NHGw[pExNjJ3L{CuOU8xNjd3L{Gg{txO M2[yWFQ5Nzd{L{m2JIg> NYHVWYZSyqCSQmO= NY\heYVzcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz M1;XUlI1PDJ|NkGz
HL-60 NWHZ[3BnSXCxcITvd4l{KEG|c3H5 NFjGbpUxNjJ3L{CuOU8xNjd3L{Gg{txO MV[0PE84Oi97NjDo NWe0c5dpyqCSQmO= MkTYbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy MYCyOFQzOzZzMx?=
KG-1a NWnPXZZnSXCxcITvd4l{KEG|c3H5 MYSwMlI2NzBwNT:wMlc2NzFizszN MX60PE84Oi97NjDo NFrxb3fDqFCEUx?= NHeyUXFqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI> MWiyOFQzOzZzMx?=
BV-173 NWHoT5ZtTnWwY4Tpc44hSXO|YYm= M4m1TFI2OC93MEDuUS=> MUW0PEBp MVhCpHBDWw>? NXvSe5ZQcW6mdXPld{Bl\WyjeXXkJIFv\CC|dYP0ZYlv\WRiUl;TJIlv[3KnYYPl MXeyOFQzOzZzMx?=
CEM MnjGSpVv[3Srb36gRZN{[Xl? MkDCNlUxNzVyMH7N MnfROFghcA>? M{TidOKhWEKV NUXmT2NxcW6mdXPld{Bl\WyjeXXkJIFv\CC|dYP0ZYlv\WRiUl;TJIlv[3KnYYPl NIOxXVYzPDR{M{[xNy=>
HL-60 NH2xSFJHfW6ldHnvckBCe3OjeR?= MkDQNlUxNzVyMH7N NIrMRmU1QCCq M1fJSuKhWEKV MX;pcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? NGrtdXozPDR{M{[xNy=>
ML-1 M1Oze2Z2dmO2aX;uJGF{e2G7 NFjIVmUzPTBxNUCwcm0> NWfGN5EzPDhiaB?= M2XxPeKhWEKV NI\CS3pqdmS3Y3XzJIRmdGG7ZXSgZY5lKHO3c4ThbY5m\CCUT2OgbY5kemWjc3W= MVWyOFQzOzZzMx?=
DLD-1 NEfnN4hHfW6ldHnvckBCe3OjeR?= MXWyOVAwPTBybl2= MmDQOFghcA>? NWTj[GVjyqCSQmO= NGS3eJJldyCwb4SgbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn MYmyOFQzOzZzMx?=
HCT-116 M17kW2Z2dmO2aX;uJGF{e2G7 M3vpTVI2OC93MEDuUS=> NX\jNFNiPDhiaB?= MmHjxsBRSlN? NVvxUZdT\G9ibn;0JIlv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= MkThNlQ1OjN4MUO=
U937-A/E-9/14/18  MoTIRZBweHSxc3nzJGF{e2G7 MViwMlAyNzBwMT:xM|ExKM7:TR?= NYnyTHR{PDhiaB?= NVnGTIhVcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MYiyOFMxODR3Nh?=
HT29 NWLGU3ZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3u4OFczKGh? NHfPOIZKSzVyPUG0NFDDuTF5OTFOwG0> M3WzTVI1OTd{ME[x
SW48 MlXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmD2O|IhcA>? NHeyN2tKSzVyPUG1MlLDuTZwMjFOwG0> MkTCNlQyPzJyNkG=
HCT116 NEfufFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TO[lczKGh? NV\NVVBXUUN3ME2xMlfDuTBwNDFOwG0> NWfwPZZUOjRzN{KwOlE>
HepG2 NXi0e3BVTnWwY4Tpc44hSXO|YYm= MmmwNE42NzFizszN MnuzNlQhcA>? Mnz0SG1UVw>? NH:zXXZ2eC2{ZXf1cIF1\WRidHjlJJJmdGG2aY\lJG9EXE5{IH3SUmEh[W6mIIDyc5RmcW5iZYjwdoV{e2mxbh?= NWrBcY1EOjRzNE[4O|Q>
LS174T NGCxNmRHfW6ldHnvckBCe3OjeR?= MYKwMlUwOSEQvF2= MYeyOEBp NXfOfFRUTE2VTx?= NWDscGN6dGWjZDD0c{BidiCrbnPy[YF{\SCxZjDPR3RPOiCuZY\lcJM> NHn4TlkzPDF2Nki3OC=>
HepG2 MUTBdI9xfG:|aYOgRZN{[Xl? M4HMflEwOTBxMUCwJO69VQ>? NHzUb4Y4KGR? MmDpSG1UVw>? Mn:0bY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M2\FO|I1OTR4OEe0
LS174T NHW4TXNCeG:ydH;zbZMhSXO|YYm= M13hTlEwOTBxMUCwJO69VQ>? NUPP[ZJqPyCm Mmm0SG1UVw>? MWHpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NFfYVlYzPDF2Nki3OC=>
QBC-939 Mn\ORZBweHSxc3nzJGF{e2G7 Ml7BNU8yOC9zMECg{txO MVW3JIQ> MoHESG1UVw>? M4nhR4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M4rG[|I1OTR4OEe0
U251 Mor4RZBweHSxc3nzJGF{e2G7 MojUNU8yOC9zMECg{txO Mn[1O{Bl MULEUXNQ M{XQUolv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M4nzdFI1OTR4OEe0
HL-60 M{PtNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;i[IMyKM7:TR?= NUSxOoFFPDhiaB?= NYjuNG5DcW6lcnXhd4V{KEd{LYDoZZNmKGOnbHyg[pJi[3Srb36= Mn;rNlQxODB|MkS=
MDA‑MB‑453 MlrCSpVv[3Srb36gRZN{[Xl? MlzFNE4zNzFizszN Mo[zO|IhcA>? MnOyZ4F2e2W|IILlMYV5eHKnc4Ppc44hd2ZiY3zheYRqdsLiMdMg MUmyN|g1PDJ{OB?=
HCC1569 MoK4SpVv[3Srb36gRZN{[Xl? NGTRN5YxNjJxMTFOwG0> NE\nPZI4OiCq NWfFXGU5[2G3c3XzJJJmNWW6cILld5Nqd25ib3[gZ4xifWSrbtMgNeKh NYXjVYdQOjN6NESyNlg>
BT‑474 Mlv6SpVv[3Srb36gRZN{[Xl? M4nSWFAvOi9zIN88US=> NIXCbY04OiCq MVTjZZV{\XNicnWt[ZhxemW|c3nvckBw\iClbHH1[IlvyqBzwrC= NGnwU4MzOzh2NEKyPC=>
AGS NF;jOHRCeG:ydH;zbZMhSXO|YYm= MWG1M|ExNzJyL{WwJO69VQ>? M4XxcFQ5yqCqwrC= M2HTcWROW09? NV34eldXcW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6yqB? MX6yN|U5Ojd6NB?=
A549 NXXDfYxvSXCxcITvd4l{KEG|c3H5 M1vpdVUwOTBxMkCvOVAh|ryP MX20POKhcMLi NVXzO|QzTE2VTx?= M{jFOYlvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0feKh NIjIRZEzOzV6Mke4OC=>
AGS  M1G1NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLBOU8yOC9{MD:1NEDPxE1? MlH5OFjDqGkEoB?= NYC2PWVHTE2VTx?= MkHtbY5lfWOnczDHNk9OKHCqYYPlJIFzemW|dNMg MnjGNlM2QDJ5OES=
Kasumi-1 MUPBdI9xfG:|aYOgRZN{[Xl? M{XDS|AvPSEQvF2= MUi0POKhcMLi M4qxNoRm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkh[29vdILlZZRm\CC5aYToJHRnNU6SLYPj NHz0ZWwzOzR7M{O0PC=>
OCI-AML3 MU\BdI9xfG:|aYOgRZN{[Xl? MnTtNk42KM7:TR?= NYjCXJBqPDkEoHlCpC=> NFHWRopl\WO{ZXHz[ZMhfGinIHPlcIwhfmmjYnnsbZR6KGOxLYTy[YF1\WRid3n0bEBV\i2QUD3zZy=> NIfaNmYzOzR7M{O0PC=>
MV4-11 NXj4VJI2SXCxcITvd4l{KEG|c3H5 MV2yMlUh|ryP M37RdlQ5yqCqwrC= NEHWXmZl\WO{ZXHz[ZMhfGinIHPlcIwhfmmjYnnsbZR6KGOxLYTy[YF1\WRid3n0bEBV\i2QUD3zZy=> M1HxTlI{PDl|M{S4
NK  NWrhOolQS3m2b4TvfIl1gSCDc4PhfS=> NH:zbmgxNjB{LUKwJO69VQ>? MknHOUBl M3SyOYRm[3KnYYPld{B1cGViY4n0c4x6fGmlIHHjeIl3cXS7IH;mJG5MKGOnbHzzJIF1KGmwdHXycYVlcWG2ZTDjc45k\W62cnH0bY9veyC{ZYP1cJRqdmdiaX6gZUBWNXOqYYDl[EBld3On4pETdoV{eG:wc3WgZ5VzfmV? M4q1U|I{OzJ6MEi4
NK  M1;zXWFxd3C2b4Ppd{BCe3OjeR?= MY[wMlAzNTJyIN88US=> MVy1JIQ> M1flcIRm[3KnYYPlJG5MKGOnbHygdJJwdGmoZYLheIlwdiCjbnSgeoli[mmuaYT5JIF{KHSqZTDjc45k\W62cnH0bY9vKGmwY4LlZZNm\A>? NEftXI0zOzN{OEC4PC=>
NK  NH\tW4dHfW6ldHnvckBCe3OjeR?= NGTmdYcxNjBzLUKwJO69VQ>? NG\6PWI2KGR? MXrjZZV{\XNiaInwc41mfGi7bHH0bY9vKG:oIF7LJINmdGy|IHnuJIEh\G:|ZfMAl5Jme3CxboPl MoTENlM{OjhyOEi=
MOLT4/DNR MY\GeY5kfGmxbjDBd5NigQ>? NG\5NI42KM7:TR?= M3zYTlQh\A>? NFKxR4Zz\WS3Y3XzJGFDS0JzIH3SUmEh\XiycnXzd4lwdg>? NV\mc|I{OjNyNkC1O|A>
Jurkat/DOX NFvmWllHfW6ldHnvckBCe3OjeR?= NXHzU2RLPSEQvF2= NY\JZY9TPCCm MojodoVlfWOnczDBRmNDOSCvUl7BJIV5eHKnc4Ppc44> Mn\vNlMxPjB3N{C=
MOLT4/DNR MlfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLTOUDPxE1? MWG0JIQ> NW\O[ZB1emWmdXPld{B1cGViSVO1NOKhfmGudXWg[o9zKGSjdX7vdpVjcWOrbjDz[Y5{cXSrdnn0fS=> NEnMfFczOzB4MEW3NC=>
Jurkat/DOX MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrKOUDPxE1? MVi0JIQ> MkPEdoVlfWOnczD0bIUhUUN3MNMgeoFtfWViZn;yJIRifW6xcoXibYNqdiC|ZX7zbZRqfmm2eR?= MXGyN|A3ODV5MB?=
ccRCC  M2PCcGFxd3C2b4Ppd{BCe3OjeR?= MVywMlAyNTFyzszN Mn:2O|IhcA>? M{nUbWROW09? MV\oZZMhdWmwaX3hcEBm\m[nY4Sgc44h[2WubDDwdo9tcW[ncnH0bY9v NYT5VnZ2OjJ6Mk[0Olc>
TNBC  MoW5RZBweHSxc3nzJGF{e2G7 NH7Q[4MxNjBzLUGw{txO MX63NkBp MnjCSG1UVw>? M1HrbohieyCvaX7pcYFtKGWoZnXjeEBwdiClZXzsJJBzd2yrZnXyZZRqd25? NXfsTpR[OjJ6Mk[0Olc>
A498 MnrERZBweHSxc3nzJGF{e2G7 Mn6zNE4xOS1zMN88US=> NEXLTVE4OiCq MVLEUXNQ MnLBbY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=> NIXCbIkzOjh{NkS2Oy=>
KIJ265T M1LQdWFxd3C2b4Ppd{BCe3OjeR?= MXKwMlAyNTFyzszN NXrZe|ZPPzJiaB?= M{DHXGROW09? NUnhSo5qcW6mdXPld{B{gW6ncnfpd5Rq[yC{ZYPwc45{\XQEoIfpeIghem:vaXTldJNqdg>? MYqyNlgzPjR4Nx?=
MDA-231 MVTBdI9xfG:|aYOgRZN{[Xl? Mlf1NE4xOS1zMN88US=> NHfBblg4OiCq M1q2TmROW09? M1LHXIlv\HWlZYOgd5lv\XKpaYP0bYMhemW|cH;ud4V{yqC5aYToJJJwdWmmZYDzbY4> MmjZNlI5OjZ2Nke=
BT-20 MXXBdI9xfG:|aYOgRZN{[Xl? MUGwMlAyNTFyzszN NFfTZ3U4OiCq M1TjW2ROW09? M4XiSYlv\HWlZYOgd5lv\XKpaYP0bYMhemW|cH;ud4V{yqC5aYToJJJwdWmmZYDzbY4> NVjaXG9LOjJ6Mk[0Olc>
U937 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojCOU0zOCEQvF2= M4HCUVI1NzR6L{eyJIg> NUjod3dNcW6mdXPld{BiKGSnY4LlZZNmKGmwIHPlcIwhfmmjYnnsbZR6KGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? NGjyfo8zOjd4N{CyNS=>
HL60 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHYeJJGPS1{MDFOwG0> NXmyO2s6OjRxNEivO|IhcA>? NVTab4JmcW6mdXPld{BiKGSnY4LlZZNmKGmwIHPlcIwhfmmjYnnsbZR6KGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? NIjENVkzOjd4N{CyNS=>
U937 M1;QdWFxd3C2b4Ppd{BCe3OjeR?= M1TIRlE2KM7:TR?= MV[yOE81QC95MjDo M4HZUYlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? Mlm4NlI4PjdyMkG=
HL60 NGTjVo9CeG:ydH;zbZMhSXO|YYm= MVixOUDPxE1? MXyyOE81QC95MjDo MX\pcoR2[2W|IHPlcIwh[XCxcITvd4l{ MUOyNlc3PzB{MR?=
LS411N  M1mxSmFxd3C2b4Ppd{BCe3OjeR?= NWq2RmJCOC53IN88US=> NUHDfGY3PzJiaB?= MnGxbY5kemWjc3XzJGZieyCvUl7BJIxmfmWu M4nRN|IzPDZzNkm1
MDA-MB-231 M1fFb2Fxd3C2b4Ppd{BCe3OjeR?= MWSxNEDPxE1? NU\yPYtEPDhiaB?= M{GwOpJm\HWlZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NYD2OVJ[OjF6OEe2PVc>
MCF-7  NEjlbZlCeG:ydH;zbZMhSXO|YYm= MYixNEDPxE1? NGC5cmg1QCCq M2PQdpJm\HWlZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NYnIT|Y{OjF6OEe2PVc>
A375 MlfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPldFJLOC53IN88US=> M1W1SVEwPS96IHS= MnfObY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? NHH1WYQzOTd7Nk[yNi=>
SKMEL1 MmTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjLNnExNjVizszN MYCxM|UwQCCm M4TyNIlvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| NH;1S3gzOTd7Nk[yNi=>
SKMEL3 MlvSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1q1WlAvPSEQvF2= M2e0O|EwPS96IHS= M3;nXolvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| Mn\WNlE4QTZ4MkK=
SKMEL28 NXjQSFFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfS[lcxNjVizszN NH\zNWQyNzVxODDk NEfnfY5qdmirYnn0d{Bxem:uaX\ldoF1cW:wIHHu[EBqdmS3Y3XzJIRq\m[ncnXueIlifGmxbjDv[kBu\Wyjbn;tZUBk\Wyucx?= MlvYNlE4QTZ4MkK=
MeWo NVHsWIRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEGzNokxNjVizszN M{DUTFEwPS96IHS= NH\0NGpqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHHu[EBqdmS3Y3XzJIRq\m[ncnXueIlifGmxbjDv[kBu\Wyjbn;tZUBk\Wyucx?= MXuyNVc6PjZ{Mh?=
B16 NIW3S|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXywMlUh|ryP M4TpUVEwPS96IHS= M3fOSIlvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| M17GbFIyPzl4NkKy
Ly 1 NET6coZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYftS2JtOjRiaB?= NV[4NZAzUUN3ME23MlMh|ryP NV7lOHp[OjF5N{KwOFk>
Ly 7 NYXoemdFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1O2SFI1KGh? M2XBVWlEPTB;MUCuO{DPxE1? NVL3fWlMOjF5N{KwOFk>
Su-DHL6 M4DHZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LhRVI1KGh? NE\SU5NKSzVy78{eNlAh|ryP M{jz[FIyPzd{MES5
Ly 10 Mme3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITTflczPCCq NI\iR3pKSzVy78{eNlAh|ryP Mk\rNlE4PzJyNEm=
RIVA NFzVfVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHmVG0zPCCq MYXJR|Ux97zgMkCg{txO NYDnU|VqOjF5N{KwOFk>
Su-DHL2 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TwblI1KGh? MVHJR|Ux97zgMkCg{txO MljINlE4PzJyNEm=
Ly 1 NH\qTolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEm5PFM1QCCq NI\4U5dKSzVyPUCuN|Qh|ryP NF\SOogzOTd5MkC0PS=>
Ly 7 NWrhb3hRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGracpQ1QCCq MXTJR|UxRTBwMEK1JO69VQ>? NXHj[YQyOjF5N{KwOFk>
Su-DHL6 M3K5Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjYXnU1QCCq MVLJR|Ux97zgMkCg{txO NUCwVpNsOjF5N{KwOFk>
Ly 10 MlHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnr1OFghcA>? NFjGO41KSzVyPUGuPEDPxE1? MYKyNVc4OjB2OR?=
RIVA NF;idm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHOVJQzPDhiaB?= NIfOeYhKSzVy78{eNlAh|ryP MVqyNVc4OjB2OR?=
Su-DHL2 M2riOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjM[21rPDhiaB?= MVPJR|UxRTF5LkSg{txO MVSyNVc4OjB2OR?=
Ly 1 NWDzWJlmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\Rd2g4OiCq M32xZ2lEPTB;MD6wNUDPxE1? NV6yTY5lOjF5N{KwOFk>
Ly 7 NHq5OXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;EbGFlPzJiaB?= M{LKcmlEPTB;MD6wNVgh|ryP M{fkXlIyPzd{MES5
Su-DHL6 NIHWbpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TXUVczKGh? NGKwOVdKSzVyPUGuOkDPxE1? NF3ZbWszOTd5MkC0PS=>
Ly 10 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXO0OFRJPzJiaB?= MYLJR|UxRTFwMjFOwG0> NXTaVmNLOjF5N{KwOFk>
RIVA NFmwZnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjaPIVHPzJiaB?= M4XMPWlEPTExvK6yNEDPxE1? MkHBNlE4PzJyNEm=
Su-DHL2 NFj2U|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLzZ2VoPzJiaB?= M2\lbmlEPTB;MUGuNkDPxE1? MUiyNVc4OjB2OR?=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 In a ALK+ KARPAS-299 murine xenograft model, Decitabine at a dose of 2.5 mg/kg causes increased apoptosis and reduced proliferation of tumor cells, and also results in demethylation of tumor suppressor p16INK4A. [2]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[1]
+ 展開

DNA synthesis assay :

The rate of DNA synthesis is measured by the incorporation of radioactive thymidine into DNA. HL-60 and KG1a cells are suspended in 2 mL RPMI medium containing 10% fetal serum in 6-well (35 mm diameter) dishes and incubated with different concentrations of corresponding drugs for 48 hours (drugs are added simultaneously). At 48 hours, 0.5 μCi [3H] thymidine (6.7 Ci/mmol) is added to each well and incubated for an additional 24 hours. The cells are placed on GF/C glass fiber filters (2.4 cm diameter), washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters containing the DNA are then dried, placed in EcoLite scintillation liquid (ICN) and the radioactivity measured using Beckman LS 6000IC scintillation counter. The IC50 is defined as the concentration of drug that inhibits 50% of the DNA synthesis of the leukemic cell lines from the dose–response curve.
細胞試験: [1]
+ 展開
  • 細胞株: HL-60 and KG1a
  • 濃度: 0-500 nM
  • 反応時間: 96 hours
  • 実験の流れ: For the growth inhibition assay, cells in log phase are placed in 5 mL of medium. Different concentrations of Decitabine are added to the medium simultaneously. Cell counts are performed at the indicated times using a model ZM Coulter Counter. The concentration that produces 50% inhibition of growth (IC50) is determined from the growth curves of the drug treated leukemic cell lines.
    (参考用のみ)
動物試験:[2]
+ 展開
  • 動物モデル: KARPAS-299 human cells are inoculated subcutaneously into the right and left flanks of the mice.
  • 製剤: Decitabine is dissolved in sterile PBS .
  • 投薬量: ≤2.5 mg/kg
  • 投与方法: Administered via i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 45 mg/mL (197.18 mM)
Water 10 mg/mL (43.81 mM)
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
water
混合させたのち直ちに使用することを推奨します。
10mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 228.21
化学式

C8H12N4O4

CAS No. 2353-33-5
保管
in solvent
別名 Deoxycytidine

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03709550 Not yet recruiting Castration Levels of Testosterone|Castration-Resistant Prostate Carcinoma|Metastatic Prostate Carcinoma in the Soft Tissue|Prostate Carcinoma Metastatic in the Bone|PSA Level Greater Than or Equal to Two|PSA Progression|Stage IV Prostate Cancer AJCC v8|Stage IVA Prostate Cancer AJCC v8|Stage IVB Prostate Cancer AJCC v8 Roswell Park Cancer Institute|National Cancer Institute (NCI) November 30 2018 Phase 1|Phase 2
NCT03691376 Not yet recruiting HLA-A*0201 Positive Cells Present|HLA-DP4 Positive Cells Present|Platinum-Resistant Ovarian Carcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Refractory Fallopian Tube Carcinoma|Refractory Ovarian Carcinoma|Refractory Primary Peritoneal Carcinoma Roswell Park Cancer Institute|National Cancer Institute (NCI) November 25 2018 Phase 1
NCT03661307 Recruiting Acute Myeloid Leukemia With FLT3/ITD Mutation|Blasts More Than 10 Percent of Bone Marrow Nucleated Cells|Blasts More Than 10 Percent of Peripheral Blood White Cells|Myelodysplastic Syndrome|Recurrent Acute Myeloid Leukemia|Recurrent Myelodysplastic Syndrome M.D. Anderson Cancer Center|National Cancer Institute (NCI) October 31 2018 Phase 1|Phase 2
NCT03679650 Recruiting Acute Myelogenous Leukemia Dana-Farber Cancer Institute|National Cancer Institute (NCI) October 11 2018 Phase 1
NCT03252457 Not yet recruiting Purpura Thrombocytopenic Idiopathic|Immune Thrombocytopenia Shandong University|Second Affiliated Hospital of Medical College Shandong University|Shandong Provincial Hospital|Qingdao Central Hospital|Chinese Academy of Medical Sciences September 1 2018 Phase 3
NCT03593915 Recruiting Myelodysplastic Syndromes (MDS) Tolero Pharmaceuticals Inc. August 29 2018 Phase 1|Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    Is S1200 a racemic mixture or a monomer?

  • 回答:

    S1200 is R form

DNA Methyltransferaseシグナル伝達経路

Tags: Decitabineを買う | Decitabine ic50 | Decitabine供給者 | Decitabineを購入する | Decitabine費用 | Decitabine生産者 | オーダーDecitabine | Decitabine化学構造 | Decitabine分子量 | Decitabine代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID